Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44

Mine, Shinichiro; Fujisaki, Takeshi; Kawahara, Chie; Tabata, Toshiharu; Iida, Takeshi; Yasuda, Manabu; Yoneda, Toshiyuki; Tanaka, Yoshiya

doi:10.1016/s0014-4827(03)00184-8

Cited by 62 publications

(35 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the present study has not shown any significant change in expression in either of these genes. These results might be partly explained by the choice of cell type in the present study, and partly due of the activity of other signal pathways, such as the Ras and ERK pathway for cyclin D1 regulation (Pruitt and Der, 2001;Jirmanova et al, 2002), TGF-b and hepatocyte growth factor for CD44 regulation (Miyazaki et al, 2002;Mine et al, 2003).…”

Section: Discussionmentioning

confidence: 83%

MRP-1/CD9 gene transduction downregulates Wnt signal pathways

et al. 2004

View full text Add to dashboard Cite

Motility-related protein-1 (MRP-1/CD9) is a transmembrane glycoprotein that has been implicated in cell adhesion, motility, proliferation, and differentiation. It has a functional role as a tumor metastatic suppressor. During tumor progression, a reduction of MRP-1/CD9 gene expression results in tumor cells with a high metastatic potential. However, the mechanism of action of MRP-1/CD9 is still unclear. We studied changes of gene expression in relation to MRP-1/CD9 gene transduction into tumor cell lines, HT1080 and A549, using microarray assays and real-time PCR. Consequently, we have demonstrated that MRP-1/ CD9 gene transduction can downregulate expression of several Wnt family genes, such as Wnt1, Wnt2b1 and Wnt5a, and their target genes, including WISP-1 (Wnt-1 induced secreted protein 1), WISP-3, c-Myc, vascular endothelial growth factor-A, and matrix metalloproteinase-26. Western blot analyses also showed that MRP-1/CD9 gene transduction downregulated expression of Wnt1 protein and its target proteins. In addition, a neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited the downregulation of Wnt signal pathways in MRP-1/CD9-transfected cells. The present study has revealed that the MRP-1/CD9 signal is located upstream of the Wnt signal pathways. Therefore, MRP-1/CD9 could suppress cell transformation including epithelial to mesenchymal transition through downregulation of Wnt1, and might suppress tumor metastasis through downregulation of Wnt5a.

show abstract

Section: Discussionmentioning

confidence: 83%

MRP-1/CD9 gene transduction downregulates Wnt signal pathways

et al. 2004

View full text Add to dashboard Cite

show abstract

“…The significance of CD44 function in promoting colonization of the bone by solid tumors is only beginning to emerge. Recently, hepatocyte growth factor-promoted adhesion of breast cancer cells to bone marrow endothelium was shown to correlate with induction of CD44 expression (20).…”

Section: Introductionmentioning

confidence: 99%

CD44 Potentiates the Adherence of Metastatic Prostate and Breast Cancer Cells to Bone Marrow Endothelial Cells

Draffin¹,

McFarlane²,

Hill³

et al. 2004

Cancer Research

236

178

View full text Add to dashboard Cite

show abstract

“…This finding contributes to the results of Hiscox et al [19] , who described a local association between the c-Met receptor and E-cadherin at the surface of tumor cells. Furthermore, it has recently been reported that HGF/SF enhances adhesion of breast cancer cells to endothelium through an upregulation of CD44 [20] .…”

Section: Introductionmentioning

confidence: 99%

Serum Levels of Hepatocyte Growth Factor/Scatter Factor in Patients with Liver Metastases from Breast Cancer

Eichbaum¹,

Rossi²,

Kaul³

et al. 2007

Tumor Biol

View full text Add to dashboard Cite

Objective: Recent studies have shown that the pleiotropic cytokine hepatocyte growth factor/scatter factor (HGF/SF) and its receptor c-Met play major roles in the malignant progression of numerous tumors. For patients with breast cancer liver metastases, increased serum levels of HGF/SF have been reported. We studied the relationship between the clinical course of the disease and the serum levels of HGF/SF in such patients. Methods: We examined 51 patients treated for breast cancer liver metastases. Serum concentrations of HGF/SF were measured before each therapy cycle and compared to the corresponding tumor marker levels. Results: Mean serum levels of HGF/SF in patients with liver metastases were increased above the reported reference levels of primary breast cancer patients. Serum levels of HGF/SF were correlated with tumor marker levels in a logarithmic relation (r = 0.47, p < 0.001). In some cases serum concentrations of HGF/SF changed similarly to the course of the corresponding tumor markers. Conclusions: Serum levels of HGF/SF are associated with the clinical course of metastatic breast cancer patients with liver metastases. Further studies are required to clarify the potential value of the HGF/SF serum concentration as a tumor marker. HGF/SF and its receptor c-Met should be further evaluated as therapeutic targets.

show abstract

Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44

Cited by 62 publications

References 42 publications

MRP-1/CD9 gene transduction downregulates Wnt signal pathways

MRP-1/CD9 gene transduction downregulates Wnt signal pathways

CD44 Potentiates the Adherence of Metastatic Prostate and Breast Cancer Cells to Bone Marrow Endothelial Cells

Serum Levels of Hepatocyte Growth Factor/Scatter Factor in Patients with Liver Metastases from Breast Cancer

Contact Info

Product

Resources

About